Tag Archives: EGRX

A Director at Eagle Pharmaceuticals Inc is Exercising Options

Today it was reported that a Director at Eagle Pharmaceuticals Inc (EGRX – Research Report), Steven Ratoff, exercised options to buy 2,340 EGRX shares at $4.04 a share, for a total transaction value of $9,453. The options were close to

Cantor Fitzgerald Reaffirms Their Hold Rating on Eagle Pharmaceuticals Inc (EGRX)

Cantor Fitzgerald analyst Brandon Folkes reiterated a Hold rating on Eagle Pharmaceuticals Inc (EGRX – Research Report) today and set a price target of $58. The company’s shares opened today at $50.04. Folkes commented: “. Post 4Q18, we are reiterating

Eagle Pharmaceuticals Inc (EGRX) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Eagle Pharmaceuticals Inc (NASDAQ: EGRX) today and set a price target of $80. The company’s shares closed yesterday at $56.90. Folkes noted: “Eagle has carved out a leading position in

Cantor Fitzgerald Maintains a Buy Rating on Eagle Pharmaceuticals Inc (EGRX)

Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Eagle Pharmaceuticals Inc (NASDAQ: EGRX) today and set a price target of $80. The company’s shares opened today at $67.36. Folkes noted: “Eagle has carved out a leading position in

Piper Jaffray Sticks to Its Buy Rating for Eagle Pharmaceuticals Inc

In a report released yesterday, David Amsellem from Piper Jaffray reiterated a Buy rating on Eagle Pharmaceuticals Inc (NASDAQ: EGRX), with a price target of $86. The company’s shares opened today at $81.82, close to its 52-week high of $85.66.

The CEO of Eagle Pharmaceuticals Inc is Exercising Options

Today, the CEO of Eagle Pharmaceuticals Inc, Scott Tarriff, exercised options of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) for $504.2K. Following this transaction Scott Tarriff’s holding in the company was increased by 8.76% to a total of $119 million. Following Scott